1 . Jameson JL, Kasper DL, Longo DL, Fauci AS, Hauser SL, Loscalzo J. "Harrison's principles of internal medicine" . McGraw-hill educationNew York; 2018.

2 . Majumdar A, Mangal NS. "Hyperprolactinemia" . Principles and Practice of Controlled Ovarian Stimulation in ART. 2015:319–28.

3 . Sheehan J, Lee C, Bodach ME, Tumialan LM, Oyesiku NM, Patil CG, et al.. "Congress of neurological surgeons systematic review and evidence-based guideline for the management of patients with residual or recurrent nonfunctioning pituitary adenomas" . Neurosurgery. 2016; 79(4):E539–40.

4 . Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al.. "Diagnosis and treatment of hyperprolactinemia: An endocrine society clinical practice guideline" . The Journal of Clinical Endocrinology & Metabolism. 2011; 96(2):273–88.

5 . Aljabri KS, Bokhari SA, Assiri FA, Alshareef MA, Khan PM. "A descriptive study to find possible correlation between pituitary magnetic resonance image findings and abnormal pituitary hormones: A retrospective single centre study in saudi community based hospital" . J Assoc Physicians India. 2019; 67(10):29–32.

6 . Hattori N, Ishihara T, Saiki Y. "Macroprolactinaemia: Prevalence and aetiologies in a large group of hospital workers" . Clin Endocrinol (Oxf). 2009; 71(5):702–8.

7 . Romijn JA. "Hyperprolactinemia and prolactinoma" . Handbook of clinical neurology. 2014; 124:185–95.

8 . Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. "A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea" . N Engl J Med. 1994; 331(14):904–9.

9 . Gorobets L, Bulanov V. "Bromocriptin and cabergolin in treatment of hyperprolactinemia in schizophrenia and schizoaffective disorder" . European Psychiatry. 2011; 26(S2):1395.

10 . Fernandez CJ, Chacko EC, Pappachan JM. "Male obesity-related secondary hypogonadism–pathophysiology, clinical implications and management" . European Endocrinology. 2019; 15(2):83.

11 . Pereira-Lima JFS, Leães CGS, Neto FMF, Barbosa MV, Silva AL, Oliveira Md. "Hyper-prolactinemia and body weight: Prevalence of obesity and overweight in patients with hyperprolactinemia" . Res J Endocrinol Metab. 2013; 1(1):2.

12 . Auriemma RS, De Alcubierre D, Pirchio R, Pivonello R, Colao A. "The effects of hyperprolactinemia and its control on metabolic diseases" . Expert review of endocrinology & metabolism. 2018; 13(2):99–106.

13 . Donadio F, Barbieri A, Angioni R, Mantovani G, Beck-Peccoz P, Spada A, et al.. "Patients with macroprolactinaemia: Clinical and radiological features" . Eur J Clin Invest. 2007; 37(7):552–7.

14 . Lee D, Oh Y, Yoon B, Choi D. "Prevalence of hyperprolactinemia in adolescents and young women with menstruation-related problems" . Obstet Gynecol. 2012; 206(3):213. e1,213. e5.

15 . Rubio-Abadal E, Del Cacho N, Saenz-Navarrete G, Arranz B, Cambra R, Cuadras D, et al.. "How hyperprolactinemia affects sexual function in patients under antipsychotic treatment" . J Clin Psychopharmacol. 2016; 36(5):422–8.

16 . Soto-Pedre E, Newey PJ, Bevan JS, Greig N, Leese GP. "The epidemiology of hyperprolactinaemia over 20 years in the Tayside region of Scotland: The prolactin epidemiology, audit and research study (PROLEARS)" . Clin Endocrinol (Oxf). 2017; 86(1):60–7.

17 . Vilar L, Vilar CF, Lyra R, da Conceicao Freitas M. "Pitfalls in the diagnostic evaluation of hyperprolactinemia" . Neuroendocrinology. 2019; 109(1):7–19.

18 . Chanson P, Maiter D. "The epidemiology, diagnosis and treatment of prolactinomas: The old and the new" . Best practice & research Clinical endocrinology & metabolism. 2019; 33(2):101290.

19 . Tariq Z, Sabie FA, Donegan D. "MON-266 the association between prolactinomas and weight gain" . Journal of the Endocrine Society. 2020; 4(Supplement_1):MON-266.

20 . Alosaimi FD, Fallata EO, Abalhassan M, Alhabbad A, Alzain N, Alhaddad B, et al.. "Prevalence and risk factors of hyperprolactinemia among patients with various psychiatric diagnoses and medications" . Int J Psychiatry Clin Pract. 2018; 22(4):274–81.

21 . Al Nuaimi A, Almazrouei R, Othman Y, Beshyah S, Aldahmani KM. "Prevalence of macroprolactinemia in patients with hyper-prolactinemia using roche elecsys platform in a large tertiary referral center in UAE" . Dubai Diabetes and Endocrinology Journal. 2021; 27(4):126–30.

22 . Soh Che, Azraini Noor Azlin, Yaacob NM, Omar J, Mohammed Jelani A, Shafii N, Tuan Ismail TS, et al.. "Global prevalence of macroprolactinemia among patients with hyperprolactinemia: A systematic review and meta-analysis" . International journal of environmental research and public health. 2020; 17(21):8199.

23 . Lu C, Hsieh C. "The importance of measuring macroprolactin in the differential diagnosis of hyperprolactinemic patients" . Kaohsiung J Med Sci. 2012; 28(2):94–9.

24 . Kasum M, Orešković S, Ćehić E, Šunj M, Lila A, Ejubović E. "Laboratory and clinical significance of macroprolactinemia in women with hyperprolactinemia" . Taiwanese Journal of Obstetrics and Gynecology. 2017; 56(6):719–24.

25 . Kavanagh-Wright L, Smith TP, Gibney J, McKenna TJ. "Characterization of macroprolactin and assessment of markers of autoimmunity in macroprolactinaemic patients" . Clin Endocrinol (Oxf). 2009; 70(4):599–605.

26 . Petakov MS, Damjanović SS, Nikolić-Durović MM, Dragojlović ZL, Obradović S, Gligorović MS, et al.. "Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. the hook effect" . J Endocrinol Invest. 1998; 21(3):184–8.

27 . Vermeulen E, D’Haens J, Stadnik T, Unuane D, Barbe K, Van Velthoven V, et al.. "Predictors of dopamine agonist resistance in prolactinoma patients" . BMC Endocrine Disorders. 2020; 20(1):1–8.

28 . Giraldi EA, Ioachimescu AG. "The role of dopamine agonists in pituitary adenomas" . Endocrinology and Metabolism Clinics. 2020; 49(3):453–74.